Augment Bone Graft Biologic – Fastest-Growing In The Portfolio

The Augment Bone Graft, based on recombinant human platelet-derived growth factor (rhPDGF-BB), was acquired from BioMimetic Therapeutics Inc. in March 2013.[See Deal] "It is a huge product. Although not the majority of Wright's biologics business, it is the fastest-growing element of the portfolio," says Wright's SVP and chief communications officer Julie Tracy. Wright secured US FDA PMA approval for the product in September 2015.